Synthesis and Evaluation of 1,3,4-Oxadiazole Derivatives as Multi-Target Neuroprotective Agents Against Alzheimer’s Disease
Oriental Journal Of Chemistry · 31.10.2026 · 5 (42) · 1988
DOI: 10.13005/ojc/420518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oriental Journal Of Chemistry, online erschienen am 30.10.2026. Verfasst von Shailesh Gulabrao Jawarkar und 8 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) represents a progressive multifactorial neurodegenerative condition marked by deterioration of cognitive function, accumulation of amyloid-β (Aβ) plaques, formation of neurofibrillary tangles, and increased oxidative stress. Existing therapeutic approaches provide only symptomatic management, underscoring the critical demand for multi-target-directed ligands (MTDLs) capable of concurrently addressing multiple pathological mechanisms. This investigation synthesized a collection of 1,3,4-oxadiazole compounds, encompassing quinoline-1,3,4-oxadiazole conjugates, coumarin-linked compounds (PP-384–PP-390), and 5-substituted-2-anilino-1,3,4-oxadiazole analogs (4a-g, 5a-g, 9a-g, and 13a-g), which were subsequently assessed for their potential as multi-target protective agents in AD. Structural characterization was accomplished through ¹H-NMR, ¹³C-NMR, IR spectroscopy, and mass spectrometry. In vitro enzymatic inhibition assays employing Ellman's spectrophotometric technique demonstrated that compound 5a from the 5-substituted-2-anilino series manifested remarkable inhibitory strength, displaying IC₅₀ concentrations of 46.9 nM for acetylcholinesterase (AChE) and 3.5 nM for butyrylcholinesterase (BuChE), representing substantially superior efficacy compared to the reference dual inhibitor Rivastigmine. The quinoline-1,3,4-oxadiazole conjugates similarly demonstrated considerable AChE suppression, with compound 5a attaining an IC₅₀ of 0.033 μM. In vivo investigations indicated that compound 5a effectively suppressed Aβ self-aggregation, diminished malondialdehyde (MDA) concentrations, and augmented glutathione (GSH) levels in cerebral tissue extracts, thereby mitigating oxidative stress. Histological analysis documented diminished neuronal deterioration alongside reduced caspase-3 and VEGF levels. Computational docking and molecular dynamics assessments validated robust binding affinities with targeted enzymes. All synthesized compounds exhibited satisfactory ADMET characteristics and compliance with Lipinski's rule of five. These observations indicate that 1,3,4-oxadiazole derivatives, notably compound 5a, represent encouraging multi-target protective candidates for AD management.
Zitieren
APA
Jawarkar, S. G., Varshney, H., Kushwaha, A., Patil, R., Mart, E. J., C, R., Gupta, M. K., Kulkarni, M. H., & Murugesan, S. (2026). Synthesis and Evaluation of 1,3,4-Oxadiazole Derivatives as Multi-Target Neuroprotective Agents Against Alzheimer’s Disease. Oriental Journal Of Chemistry, 5(42), 1988. https://doi.org/10.13005/ojc/420518
Vancouver
Jawarkar SG, Varshney H, Kushwaha A, Patil R, Mart EJ, C R, et al. Synthesis and Evaluation of 1,3,4-Oxadiazole Derivatives as Multi-Target Neuroprotective Agents Against Alzheimer’s Disease. Oriental Journal Of Chemistry. 2026;5(42):1988. doi:10.13005/ojc/420518
BibTeX
@article{Jawarkar2026,
author = {Jawarkar, Shailesh Gulabrao and Varshney, Himank and Kushwaha, Aman and Patil, Ramanand and Mart, E. Joel and C, Renish. and Gupta, Mahesh Kumar and Kulkarni, Mrunalini Harish and Murugesan, Sudha},
title = {Synthesis and Evaluation of 1,3,4-Oxadiazole Derivatives as Multi-Target Neuroprotective Agents Against Alzheimer’s Disease},
journal = {Oriental Journal Of Chemistry},
year = {2026},
volume = {5},
number = {42},
pages = {1988},
doi = {10.13005/ojc/420518}
}
EUVIMED